Rise in applications for medicines in 2006
Following a recent board meeting, the European Medicines Agency (EMEA) has reported an increase in applications in 2006. The initial application forecast for the year has been revised from 61 to 91 applications, an increase of 49%.
Following a recent board meeting, the European Medicines Agency (EMEA) has reported an increase in applications in 2006. The initial application forecast for the year has been revised from 61 to 91 applications, an increase of 49%.
Thomas LÅ¡nngren, EMEA executive director, sats that the unforeseen increase is due in part to applications for new innovative medicines and for new uses of approved medicines, and in part to some additional generic, biosimilar and multiple applications.
Public health obligations for the Agency that will have an impact in 2007 include the implementation of the new regulation on medicines for children, support for small and medium-sized enterprises and increased work for orphan medicinal products. There is also the need for continued work on Euro-pean telematics projects such as EudraPharm, the community database on medicinal products, and EudraVigilance, the community data processing network for adverse drug reactions, EMEA says.
The agency will publish regular information about its activities in support of small and medium-sized enterprises (SMEs). This will include the names of companies that have been assigned SME status by the agency. The aim is to highlight the EMEA's work in supporting SMEs and to encourage other eligible companies to come forward.